Shawn Tomasello - Net Worth and Insider Trading

Shawn Tomasello Net Worth

The estimated net worth of Shawn Tomasello is at least $11 Million dollars as of 2026-08-10. Shawn Tomasello is the Chief Commercial Officer of Kite Pharma Inc and owns about 61,068 shares of Kite Pharma Inc (KITE) stock worth over $11 Million. Shawn Tomasello is the Director of Diplomat Pharmacy Inc and owns about 44,537 shares of Diplomat Pharmacy Inc (DPLO) stock worth over $178,148. Shawn Tomasello is also the Director of Cabaletta Bio Inc and owns about 22,725 shares of Cabaletta Bio Inc (CABA) stock worth over $62,835. Details can be seen in Shawn Tomasello's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Shawn Tomasello has not made any transactions after 2026-01-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Shawn Tomasello

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

KITE Kite Pharma Inc

98% of holdings · $11.0M

DPLO Diplomat Pharmacy Inc

2% of holdings · $178K

CABA Cabaletta Bio Inc

1% of holdings · $63K

Shawn Tomasello Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Shawn Tomasello owns 11 companies in total, including Principia Biopharma Inc (PRNB) , UroGen Pharma Ltd (URGN) , and Abeona Therapeutics Inc (ABEO) among others .

Click here to see the complete history of Shawn Tomasello’s form 4 insider trades.

Insider Ownership Summary of Shawn Tomasello

Ticker	Company	Transaction Date	Type of Owner
PRNB	Principia Biopharma Inc	2020-09-28	director
URGN	UroGen Pharma Ltd	2019-01-01	director
ABEO	Abeona Therapeutics Inc	2020-04-15	director
		2020-02-10	director
		2017-10-03	Chief Commercial Officer
		2022-01-01	director
		2020-12-10	director
		2022-12-15	director
		2022-03-29	director
		2026-01-21	director
		2022-03-29	director

Shawn Tomasello Latest Holdings Summary

Shawn Tomasello currently owns a total of 3 stocks. Among these stocks, Shawn Tomasello owns 61,068 shares of Kite Pharma Inc (KITE) as of September 25, 2017, with a value of $11 Million and a weighting of 97.85%. Shawn Tomasello owns 44,537 shares of Diplomat Pharmacy Inc (DPLO) as of October 2, 2019, with a value of $178,148 and a weighting of 1.59%. Shawn Tomasello also owns 22,725 shares of Cabaletta Bio Inc (CABA) as of January 21, 2026, with a value of $62,835 and a weighting of 0.56%.

Latest Holdings of Shawn Tomasello

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KITE	Kite Pharma Inc	2017-09-25	61,068	179.79	10,979,416
DPLO	Diplomat Pharmacy Inc	2019-10-02	44,537	4.00	178,148
CABA	Cabaletta Bio Inc	2026-01-21	22,725	2.77	62,835

Holding Weightings of Shawn Tomasello

Shawn Tomasello Form 4 Trading Tracker

According to the SEC Form 4 filings, Shawn Tomasello has made a total of 0 transactions in Kite Pharma Inc (KITE) over the past 5 years. The most-recent trade in Kite Pharma Inc is the sale of 4,203 shares on September 25, 2017, which brought Shawn Tomasello around $755,111.

According to the SEC Form 4 filings, Shawn Tomasello has made a total of 0 transactions in Diplomat Pharmacy Inc (DPLO) over the past 5 years. The most-recent trade in Diplomat Pharmacy Inc is the sale of 859 shares on October 2, 2019, which brought Shawn Tomasello around $4,158.

According to the SEC Form 4 filings, Shawn Tomasello has made a total of 1 transactions in Cabaletta Bio Inc (CABA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Cabaletta Bio Inc is the acquisition of 22,725 shares on January 21, 2026, which cost Shawn Tomasello around $50,222.

Insider Trading History of Shawn Tomasello

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Shawn Tomasello Trading Performance

GuruFocus tracks the stock performance after each of Shawn Tomasello's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Shawn Tomasello is 33.76%. GuruFocus also compares Shawn Tomasello's trading performance to market benchmark return within the same time period. The performance of stocks bought by Shawn Tomasello within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Shawn Tomasello's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Shawn Tomasello

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	24.36
Relative Return to S&P 500(%)	23.87

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Shawn Tomasello owns.

- KITE - DPLO - CABA

View KITE Analysis

Shawn Tomasello Ownership Network

Ownership Network List of Shawn Tomasello

No Data

Ownership Network Relation of Shawn Tomasello

Shawn Tomasello Owned Company Details

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Shawn Tomasello is the director of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does UroGen Pharma Ltd do?

Who are the key executives at UroGen Pharma Ltd?

Shawn Tomasello is the director of UroGen Pharma Ltd. Other key executives at UroGen Pharma Ltd include Chief Medical Officer Mark Schoenberg , General Counsel Jason Drew Smith , and Chief Financial Officer Chris Degnan .

UroGen Pharma Ltd (URGN) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made no insider transaction in UroGen Pharma Ltd (URGN). Other recent insider transactions involving UroGen Pharma Ltd (URGN) include a net sale of 73,777 shares made by Mark Schoenberg , a net sale of 16,521 shares made by Jason Drew Smith , and a net sale of 2,203 shares made by Chris Degnan .

In summary, during the past 3 months, insiders sold 25,222 shares of UroGen Pharma Ltd (URGN) in total and bought 0 shares, with a net sale of 25,222 shares. During the past 18 months, 92,501 shares of UroGen Pharma Ltd (URGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 92,501 shares.

UroGen Pharma Ltd (URGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

UroGen Pharma Ltd Insider Transactions

No Available Data

What does Abeona Therapeutics Inc do?

Who are the key executives at Abeona Therapeutics Inc?

Shawn Tomasello is the director of Abeona Therapeutics Inc. Other key executives at Abeona Therapeutics Inc include Chief Financial Officer Joseph Walter Vazzano , Chief Commercial Officer Madhav Vasanthavada , and SVP & General Counsel Brendan M. O'malley .

Abeona Therapeutics Inc (ABEO) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made no insider transaction in Abeona Therapeutics Inc (ABEO). Other recent insider transactions involving Abeona Therapeutics Inc (ABEO) include a net sale of 438,751 shares made by Vishwas Seshadri , a net sale of 163,890 shares made by Joseph Walter Vazzano , and a net sale of 74,711 shares made by Brendan M. O'malley .

In summary, during the past 3 months, insiders sold 312,769 shares of Abeona Therapeutics Inc (ABEO) in total and bought 0 shares, with a net sale of 312,769 shares. During the past 18 months, 936,090 shares of Abeona Therapeutics Inc (ABEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 936,090 shares.

Abeona Therapeutics Inc (ABEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Abeona Therapeutics Inc Insider Transactions

No Available Data

What does Diplomat Pharmacy Inc do?

Who are the key executives at Diplomat Pharmacy Inc?

Shawn Tomasello is the director of Diplomat Pharmacy Inc. Other key executives at Diplomat Pharmacy Inc include director & Chairman and CEO Brian T Griffin , director & Chief Financial Officer Sean Whelan , and director & EVP of Operations Jeffrey M Rowe .

Diplomat Pharmacy Inc (DPLO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Diplomat Pharmacy Inc (DPLO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Diplomat Pharmacy Inc (DPLO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Diplomat Pharmacy Inc (DPLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Diplomat Pharmacy Inc Insider Transactions

No Available Data

What does Kite Pharma Inc do?

Who are the key executives at Kite Pharma Inc?

Shawn Tomasello is the Chief Commercial Officer of Kite Pharma Inc. Other key executives at Kite Pharma Inc include EVP & Business Development Helen Susan Kim , EVP & Technical Operations Timothy L. Moore , and Chief Operating Officer Cynthia M Butitta .

Kite Pharma Inc (KITE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kite Pharma Inc (KITE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kite Pharma Inc (KITE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kite Pharma Inc (KITE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kite Pharma Inc Insider Transactions

No Available Data

What does Gamida Cell Ltd do?

Who are the key executives at Gamida Cell Ltd?

Shawn Tomasello is the director of Gamida Cell Ltd. Other key executives at Gamida Cell Ltd include Chief Financial Officer Mary Theresa Coelho , CMO & Chief Scientific Officer Ronit Simantov , and director & President and CEO Abigail L. Jenkins .

Gamida Cell Ltd (GMDAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Gamida Cell Ltd (GMDAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Gamida Cell Ltd (GMDAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Gamida Cell Ltd (GMDAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gamida Cell Ltd Insider Transactions

No Available Data

What does 4D Molecular Therapeutics Inc do?

Who are the key executives at 4D Molecular Therapeutics Inc?

Shawn Tomasello is the director of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include director & Chief Executive Officer David Kirn , Chief Legal and HR Officer Scott Bizily , and VP & Finance and Controller Ashoo Gupta .

4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 28,774 shares made by Scott Bizily , a net sale of 214,258 shares made by David Kirn , and a net sale of 779 shares made by Ashoo Gupta .

In summary, during the past 3 months, insiders sold 230,634 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 230,634 shares. During the past 18 months, 243,811 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 243,811 shares.

4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

4D Molecular Therapeutics Inc Insider Transactions

No Available Data

What does TCR2 Therapeutics Inc do?

Who are the key executives at TCR2 Therapeutics Inc?

Shawn Tomasello is the director of TCR2 Therapeutics Inc. Other key executives at TCR2 Therapeutics Inc include 10 percent owner Kevin Tang , director & 10 percent owner Ansbert Gadicke , and 10 percent owner Mpm Asset Management Llc .

TCR2 Therapeutics Inc (TCRR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TCR2 Therapeutics Inc (TCRR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TCR2 Therapeutics Inc (TCRR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TCR2 Therapeutics Inc (TCRR)'s detailed insider trading history can be found in Insider Trading Tracker table.

TCR2 Therapeutics Inc Insider Transactions

No Available Data

What does AlloVir Inc do?

Who are the key executives at AlloVir Inc?

Shawn Tomasello is the director of AlloVir Inc. Other key executives at AlloVir Inc include director & 10 percent owner & See Remarks Vikas Sinha , General Counsel Edward Miller , and Chief Accounting Officer Brett R Hagen .

AlloVir Inc (ALVR) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made no insider transaction in AlloVir Inc (ALVR). Other recent insider transactions involving AlloVir Inc (ALVR) include a net sale of 303 shares made by Vikas Sinha , a net sale of 106 shares made by Edward Miller , and a net sale of 96 shares made by Brett R Hagen .

In summary, during the past 3 months, insiders sold 0 shares of AlloVir Inc (ALVR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 505 shares of AlloVir Inc (ALVR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 505 shares.

AlloVir Inc (ALVR)'s detailed insider trading history can be found in Insider Trading Tracker table.

AlloVir Inc Insider Transactions

No Available Data

What does Cabaletta Bio Inc do?

Who are the key executives at Cabaletta Bio Inc?

Shawn Tomasello is the director of Cabaletta Bio Inc. Other key executives at Cabaletta Bio Inc include CHIEF COMMERCIAL OFFICER Steve Gavel , General Counsel Michael Gerard , and EVP & Science & Technology Gwendolyn Binder .

Cabaletta Bio Inc (CABA) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made 1 insider transaction in Cabaletta Bio Inc (CABA) with a net purchase of 22,725. Other recent insider transactions involving Cabaletta Bio Inc (CABA) include a net purchase of 45,000 shares made by Steven Nichtberger , a net purchase of 22,170 shares made by Steve Gavel , and a net purchase of 11,312 shares made by Gwendolyn Binder .

In summary, during the past 3 months, insiders sold 0 shares of Cabaletta Bio Inc (CABA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cabaletta Bio Inc (CABA) were sold and 132,073 shares were bought by its insiders, resulting in a net purchase of 132,073 shares.

Cabaletta Bio Inc (CABA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cabaletta Bio Inc Insider Transactions

No Available Data

What does Kalaris Therapeutics Inc do?

Who are the key executives at Kalaris Therapeutics Inc?

Shawn Tomasello is the director of Kalaris Therapeutics Inc. Other key executives at Kalaris Therapeutics Inc include director & 10 percent owner Srinivas Akkaraju , Chief Accounting Officer Brett R Hagen , and 10 percent owner Samsara Opportunity Fund Gp, Llc .

Kalaris Therapeutics Inc (KLRS) Insider Trades Summary

Over the past 18 months, Shawn Tomasello made no insider transaction in Kalaris Therapeutics Inc (KLRS). Other recent insider transactions involving Kalaris Therapeutics Inc (KLRS) include a net purchase of 724,147 shares made by Srinivas Akkaraju , and a net sale of 2,822 shares made by Brett R Hagen .

In summary, during the past 3 months, insiders sold 0 shares of Kalaris Therapeutics Inc (KLRS) in total and bought 244,300 shares, with a net purchase of 244,300 shares. During the past 18 months, 2,822 shares of Kalaris Therapeutics Inc (KLRS) were sold and 724,147 shares were bought by its insiders, resulting in a net purchase of 721,325 shares.

Kalaris Therapeutics Inc (KLRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kalaris Therapeutics Inc Insider Transactions

No Available Data

Shawn Tomasello Mailing Address

Above is the net worth, insider trading, and ownership report for Shawn Tomasello. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Shawn Tomasello's mailing address is: Sunnyvale Ca 94085.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.